# Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Source: https://onco.cc/trials/nct05413850/  
OnCo record `nct05413850` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of FAP-2286 in prostate cancer, run by Blue Earth Therapeutics Ltd, now recruiting.

## Summary

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection is a phase 1/2 interventional study registered as NCT05413850 by Blue Earth Therapeutics Ltd, with 82 participants planned, started 2022-07-20 and due to reach its primary completion in 2026-08-27. Interventions recorded: Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only). Conditions listed: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05413850
- Phase: 1/2
- Setting: An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer
- Sponsor: Blue Earth Therapeutics Ltd
- Enrolled: 82

## Sources

- ClinicalTrials.gov NCT05413850: https://clinicaltrials.gov/study/NCT05413850

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [FAP-2286 (177Lu / 68Ga)](https://onco.cc/drugs/fap-2286/)

---
JSON: https://onco.cc/api/v1/entities/nct05413850.json